[1] Wang GQ, Duan ZP, Wang FS, et al.The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol(实用病肝脏杂志), 2020, 23(1): 9-32. [2] Seto WK, Lo YR, Pawlotsky JM, et al.Chronic hepatitis B virus infection[J]. Lancet, 2018, 392: 2313-2324. [3] Liu J, Liang W, Jing W, et al.Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. [4] Liu Y, Xu ZH, Liu LM, et al.Genotypic and phenotypic characteristics of multidrug-resistant hepatitis B virus infection in Chinese hepatitis B patients[J]. Med J Chin PLA(解放军医学杂志), 2012, 37(6): 539-543. [5] Zhou Y, Liu Y, Xu D, et al.Characteristics and rescue therapy strategies of multidrug-resistant HBV infection[J]. Infect Dis Info(传染病信息), 2017, 30(2): 109-114. [6] Ye XL, Liu Y, Xu DP.Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus[J]. J Prac Hepatol(实用肝脏病杂志), 2015, 18(3): 312-316. [7] De Fraga RS, Van Vaisberg V, Mendes LCA, et al.Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review[J]. J Gastroenterol, 2020, 55: 496-514. [8] Feng XJ, Huang Y, Chen PS, et al.Market analysis of anti-hepatitis B virus drugs[J]. China Biotechnology, 2019, 39(1): 90-98. [9] Liu Y, Liu W, Li X, et al.Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients[J]. Antivir Ther, 2014, 19(6): 551-558. [10] Luo A, Jiang X, Ren H.Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(51): e13596. [11] Jaffe A, Brown RS Jr.A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women[J]. Gastroenterol Hepatol (NY), 2017, 13(3): 154-163. [12] Charlton MR, Alam A, Shukla A, et al.An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia[J]. J Gastroenterol, 2020, 55(9): 811-823. [13] Locarnini S, Zoulim F.Molecular genetics of HBV infection[J]. Antivir Ther, 2010, 15(suppl 3): 3-14. [14] Zoulim F, Locarnini S.Hepatitis B virus resistance to nucleos(t)ide analogues[J]. Gastroenterology, 2009, 137(5): 1593-1608. [15] Zoulim F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J]. Antiviral Res, 2004, 64(1): 1-15. [16] Zhou P, Qu SY.Research status of nucleoside (acid) analogues in the treatment of viral drug resistance sites in patients with chronic hepatitis B[J]. Chinese Journal of Integrated Traditional and Western Medi-cine on Liver Diseases(中西医结合肝病杂志), 2020, 30(2): 188-192. [17] Liu Y, Wang C, Zhong Y, et al.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection[J]. J Viral Hepat, 2011, 18(4): e29-e39. [18] Liang LY, Wong GL.Unmet need in chronic hepatitis B management[J]. Clin Mol Hepatol, 2019, 25(2): 172-180. [19] Wang X, Liu X, Dang Z, et al.Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis b patients: a syste-matic review and meta-analysis[J]. Gut Liver, 2020, 14(2): 232-247. [20] Amini-Bavil-Olyaee S, Vucur M, Luedde T, et al. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains[J]. J Virol, 2010, 84(2): 1026-1033. [21] Huang BX, Liu Y, Fan ZP, et al.Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations[J]. World J Gastroenterol, 2020, 26(35): 5314-5327. [22] Ma Y, Yuan Y, Ma X, et al.Association between clinical features and ymdd mutations in patients with chronic hepatitis b following lamivudie therapy[J]. Exp Therapeutic Med, 2016, 12(2): 847-853. [23] Ji D, Liu Y, Li L, et al.The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation[J]. J Clin Virol, 2012, 54(1): 66-72. [24] Liu Y, Xu Z, Wang Y, et al.rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus[J]. PLoS One, 2014, 9(2): e89015. [25] Wang C, Yu S, Zhang Y, et al.Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy[J]. Exp Ther Med, 2019,17(4): 2473-2484. [26] Quercia R, Perno CF, Koteff J, et al.Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 Infection[J]. J Acquir Immune Defic Syndr, 2018, 78(2): 125-135. [27] Yip TC, Lai JC, Wong GL.Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?[J]. J Gastroenterol, 2020, 55(11): 1023-1036. [28] Tacke F, Kroy DC.Treatment for hepatitis B in patients with drug resistance[J]. Ann Transl Med, 2016, 4(18): 334. [29] Chen RJ, Liu Y, Li XD, et al.Analysis for clinical detection and phenotypic features of HBV mutants resistant to both lamivudine and adefovir[J]. J Prac Hepatol(实用肝脏病杂志), 2018, 31(3): 215-219. [30] Zhao L, Li X, Cheng Y, et al.Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation[J]. Antiv-iral Res, 2018, 154: 26-34. [31] Yang S, Xing HC, Cheng J.Progress in hepatitis B virus resistance to nucleos(t)ide analogues[J]. Chin J Exp Clin Infect Dis (Electronic Edition)(中华实验和临床感染病杂志(电子版)), 2018, 12(1): 1-6. [32] Ahn SH, Park YK, Park ES, et al.The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol, 2014, 88(12): 6805-6818. [33] Liu Y, Li X, Xin S, et al.The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil[J]. J Viral Hepat, 2015, 22(3): 328-334. [34] Liu Y, Zhou Y, Li X, et al.Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice[J]. Emerg Microbes Infect, 2019, 8(1): 354-365. [35] Yin FF, Wu Z, Fang W, et al.Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment[J]. J Gen Virol, 2015, 96(11): 3302-3312. [36] Liu Y, Corsa AC, Buti M, et al.No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment[J]. J Viral Hepat, 2017, 24(1): 68-74. [37] Buti M, Tsai N, Petersen J, et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2015, 60(5): 1457-1464. [38] Cathcart AL, Chan HL, Bhardwaj N, et al.No resisitance to tenofovir alafenanmide detacted through 96 weeks of treatment in patients with chronic hepatitis B infection[J]. Antimicrob Agents Chemothe, 2018, 62(10): 1064-1076. [39] Mokaya J, Maponga TG, McNaughton AL, et al. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults[J]. J Clin Virol, 2020, 129: 104548. [40] Liu Y, Wang CM, Cheng J, et al.Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility[J]. Chin Med J (Engl), 2009, 122(13): 1585-1586. [41] Qin B, Budeus B, Cao L, et al.The amino acid substitutions rtP177G and rtF249 A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J]. Antiviral Res, 2013, 97(2): 93-100. [42] Park ES, Lee AR, Kim DH, et al.Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(6): 1093-1102. [43] Blackard JT, Kwara A, Sherman KE.In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 71(6): 1259-1260. [44] Liu Y, Miller MD, Kitrinos KM.Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro[J]. Antiviral Res. 2017,139: 25-31. [45] Liaw YF, Leung N, Kao JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update[J]. Hepatology International, 2008, 2(3): 263-283. [46] Shao JM, Tang XF, Liu Y, et al.Progress in rescue therapy of tenofovir disoproxil fumarate for chronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil[J]. Infect Dis Info(传染病信息), 2017, 30(6): 371-375. |